Abstract:Atherosclerosis is a chronic inflammatory disease of the arterial wall with hypercholesterolemia and inflammation representing two major pillars in its pathophysiology. A decade ago, studies unraveled how hypercholesterolemia influences inflammation and revealed that lipids orchestrate leukocyte homeostasis. Hypercholesterolemia-associated monocytosis and neutrophilia directly correlate with lesional leukocyte counts and lesion dimension in mice and with the incidence of cardiovascular events in humans.[1] [2] [3] In mice, for example, counts of circulating Ly6C hi inflammatory monocytes correlate with atherosclerotic lesion burden.[2] [4] Similarly, circulating neutrophil counts expand under hypercholesterolemia correlating with atherosclerotic plaque size and lesional neutrophil accumulation.[1] [5] [6] Analogous associations were already found in the 1970s, when it was noticed that peripheral leukocyte counts predict future cardiovascular events.[7] Very recently, these observations were extended by providing proof for the causality between high neutrophil counts and the risk for cardiovascular morbidity across several end points.[8] [9] Formyl-peptide receptor 1 (FPR1) is an ancient receptor for bacterial derived motifs including the needle cap protein of Yersinia pestis [10] as well as of formylated peptides that are released from all bacteria. Yet, given the fact that eukaryote mitochondria are of bacterial origin,[11] it is not surprising that mitochondrial damage in the case of cell necrosis releases host-derived formyl-peptides. Among circulating immune cells, FPR1 is predominantly expressed on neutrophils and hence lack of this receptor impairs neutrophil recruitment in the context of bacterial infections and tissue necrosis.[12] [13] [14] However, the role of FPR1 in vascular inflammation remains thus far unknown. Hence, we crossed FPR1-deficient ( Fpr1 −/− ) and apolipoprotein E-deficient ( Apoe −/− ) animals and fed these mice western diet (WD) or normal chow diet for 4 weeks and performed subsequent flow cytometric and histological sample assessment ([Fig. 1A]). Mice were sacrificed and body weight, plasma cholesterol, and triglyceride levels were determined but remained unaltered between the groups (data not shown). Subsequent analysis of leukocyte counts in blood, however, revealed hypercholesterolemia-associated neutrophilia only in Apoe −/− but not in Apoe −/− Fpr1 −/− animals ([Fig. 1B]). Interestingly, this effect could not be recapitulated in bone marrow or spleen of Apoe −/− Fpr1 −/− mice ([Fig. 1C, D]). The latter indicates a critical role for FPR1 in controlling neutrophil numbers in blood under hyperlipidemic conditions. Given that the frequency of annexin V + neutrophils in blood of FPR1 competent and deficient mice was not different, we concluded that neutrophil apoptosis was likely no contributor to lower neutrophil blood counts in FPR1-deficient mice ([Fig. 1E]). Importantly, the number of colony forming units (CFU) in bone marrow cells increased upon hyperlipidemia but remained unchanged between Apoe −/− and Apoe −/− FPR1 −/− mice ([Fig. 1F]). With apoptosis and production being unaltered, we assumed that possibly the mobilization of neutrophils from the bone marrow is impaired. To test this idea, we performed bromodeoxyuridine (BrdU) pulse labeling and quantified the appearance of BrdU-positive neutrophils in blood over time. In agreement with our hypothesis, neutrophils from FPR1-defcient mice exhibited impaired mobilization capacities ([Fig. 1G]). Preclinical and recent clinical data strongly suggest a correlation between circulating neutrophil counts and cardiovascular disease burden.[1] [8] Here, we analyzed a published human scRNAseq dataset of advanced atherosclerotic lesions (GSE155512,[15]) and an unpublished murine scRNAseq dataset of brachiocephalic arteries from Apoe −/− mice fed with WD for 16 weeks for cell-specific FPR1 expression. In both datasets, FPR1 expression was restricted to myeloid cells and in particular to neutrophils as evident from clustering of CSF1R and S100A8 together with FPR1 ([Fig. 1H] and data not shown). Further, we studied how lack of FPR1 impacts on early atherogenesis and lesion composition. Therefore, we analyzed the number of neutrophils and macrophages in aortic cell suspensions of WD fed Apoe −/− and Apoe −/− Fpr1 −/− mice. H -Abstract Truncated-

FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis

FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis.

Neutrophil dynamics in pulmonary fibrosis: pathophysiological and therapeutic perspectives

Functional Pdgfra fibroblast heterogeneity in normal and fibrotic mouse lung

Sfrp1 inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts

Angiotensin-converting Enzyme Defines Matrikine-Regulated Inflammation and Fibrosis

Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts.

The FMS-like tyrosine kinase-3 ligand/lung dendritic cell axis contributes to regulation of pulmonary fibrosis

The long non-coding RNA PFI protects against pulmonary fibrosis by interacting with splicing regulator SRSF1

PDGFR{alpha}-positive fibroblasts display a proinflammatory phenotype in infection-driven exacerbation of experimental lung fibrosis

Disruption of Prostaglandin F2 α Receptor Signaling Attenuates Fibrotic Remodeling and Alters Fibroblast Population Dynamics in A Preclinical Murine Model of Idiopathic Pulmonary Fibrosis

The role of GPR87 in Pulmonary Fibrosis

The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis

Lack of Formyl-peptide Receptor 1 Mitigates Atherosclerosis in Hyperlipidemic Mice

Pneumocystis carinii infection drives upregulation of Fn1 expression that causes pulmonary fibrosis with an inflammatory response

Identification of FGFR4 as a regulator of myofibroblast differentiation in pulmonary fibrosis

MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution

Genetic ablation of the fpr1 gene confers protection from smoking-induced lung emphysema in mice

Characterization of Fibroblast-Specific Protein 1 in Pulmonary Fibrosis

Inhibition of tyrosine kinase Fgr prevents radiation-induced pulmonary fibrosis (RIPF)

S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung